Melanoma, Version 4.2014
Daniel G. Coit, John A. Thompson, Robert H.I. Andtbacka et al. · Journal of the National Comprehensive Cancer Network · 2014
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.
Cited by 78 works. doi:10.6004/jnccn.2014.0066 Open-access PDF
Authors
- Daniel G. Coit
- John A. Thompson
- Robert H.I. Andtbacka
- Christopher James Anker
- Christopher Keram Bichakjian
- William Edgar Carson
- Gregory A. Daniels
- ADIL I. DAUD
- Dominick J. DiMaio
- Martin D. Fleming
- Rene C. Gonzalez
- Valerie Guild
- Allan C. Halpern
- Frank Stephen Hodi
- Mark C. Kelley
- Nikhil I. Khushalani
- Ragini Reiney Kudchadkar
- Julie R. Lange
- Mary C. Martini
- Anthony J. Olszanski
References
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Somatic Activation of KIT in Distinct Subtypes of Melanoma
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006
- Fraction size in external beam radiation therapy in the treatment of melanoma
- Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group